

AMENDMENT TO THE CLAIMS:

The following claim listing will replace all previous listings of the claims:

1. (Currently amended) An isolated, synthetic or recombinant χ -conotoxin peptide comprising the following sequence of amino acids:

Xaal Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3

where Xaal is a N-terminal pyroglutamate (pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is Asn or a deletion; or such a sequence in which one or more Cys is replaced with its corresponding D-amino acid ~~and/or one or more amino acid residues other than Cys has undergone a side chain modification, and/or Pro has been replaced with 4-hydroxyproline, and/or Tyr is substituted with 4-methoxy tyrosine;~~ or a salt, ~~ester, or amide or prodrug~~ thereof.

2. (Currently amended) The peptide according to claim 1 consisting of the following sequence of amino acids:

Xaal Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3

where Xaal is a N-terminal pyroglutamate (pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is Asn or a deletion; or such a sequence in which one or more Cys is replaced with its corresponding D-amino acid ~~and/or one or more amino acid residues other than Cys has undergone a side chain modification, and/or Pro has been replaced with 4-hydroxyproline, and/or Tyr is substituted with 4-methoxy tyrosine;~~ or a salt, ~~ester, or amide or prodrug~~ thereof.

3. (Currently amended) The peptide according to claim 1 wherein ~~said sidechain comprises replacement of Tyr with 4-methoxy tyrosine and/or replacement of Pro with 4-hydroxyproline~~ Pro has been replaced with 4-hydroxyproline.

4. (Currently amended) The peptide according to claim 1 having the following sequence of amino acids

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys SEQ ID NO. 4

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Xaa5 SEQ ID NO. 5;

Xaal Gly Val Cys Cys Gly Xaa4 Lys Leu Cys His Xaa3 Cys SEQ ID NO. 6;

~~Xaal Asn Gly Val Cys Cys Gly Xaa4 Lys Leu Cys His Xaa3 Cys SEQ ID NO. 7~~

~~Xaal Asn Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys~~ SEQ ID NO. 8

or

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys-OH SEQ ID NO. 9;

where Xaal ~~refers to pyroglutamic acid~~ is N-terminal pGlu, Xaa3 ~~refers to~~ is 4-hydroxyproline, Xaa4 ~~refers to~~ is 4-methoxy tyrosine, Xaa5 ~~refers to~~ is D-cysteine and -OH indicates a free acid C terminal.

5. (Withdrawn and currently amended) The peptide according to claim 1 having the following sequence of amino acids

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys-OH SEQ ID NO. 10

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys SEQ ID NO. 11

where Xaal ~~refers to~~ is D-pyroglutamic acid DpGlu, Xaa3 ~~refers to~~ is 4-hydroxyproline and -OH indicates a free acid C terminal.

6. (Previously presented) A composition comprising the peptide of any one of claims 1 to 5 together with pharmaceutically acceptable carrier or diluent.

7. (Original) The composition of claim 6 further comprising one or more other active agents.

8-10. (Canceled)

11. (Withdrawn and currently amended) A method for the treatment or prophylaxis of urinary or cardiovascular conditions or diseases, or mood disorders, or for the treatment or control of acute, chronic and/or neuropathic pain, migraine or inflammation in a mammal comprising administering to the mammal an effective amount of an isolated, synthetic or recombinant χ -conotoxin peptide of any one of claims 1-5 or 15-16.

12-14. (Canceled)

15. (Previously presented) An isolated, synthetic or recombinant χ -conotoxin peptide or a salt, ester or amide thereof, wherein said peptide comprises the following amino acid sequence:

pGlu Gly Val Cys Cys Gly Tyr Lys Leu Cys His Hyp Cys (SEQ ID NO: 4).

16. (Previously presented) An isolated, synthetic or recombinant amidated χ -conotoxin peptide, wherein said peptide comprises the following amino acid sequence:

pGlu Gly Val Cys Cys Gly Tyr Lys Leu Cys His Hyp Cys (SEQ ID NO: 4),
and wherein the C-terminal Cys residue is amidated.

17. (New) A method for the treatment or control of acute, chronic and/or neuropathic pain, migraine or inflammation in a mammal comprising administering to the mammal an effective amount of an isolated, synthetic or recombinant χ -conotoxin peptide of any one of claims 1-5 or 15-16.

18. (New) The method of claim 17, wherein the neuropathic pain is associated with surgery (post operative pain), gut, cancer, diabetic, phantom limb, nerve damage, inflammatory pain and peripheral nerve associated pain.

19. (New) The method of claim 17, wherein the peptide is administered substantially simultaneously or sequentially with other agents useful in the treatment of said conditions, diseases or disorders, or said pain, migraine or inflammation.

20. (New) The method of claim 11, wherein the neuropathic pain is associated with surgery (post operative pain), gut, cancer, diabetic, phantom limb, nerve damage, inflammatory pain and peripheral nerve associated pain.

21. (New) The method of claim 11, wherein the peptide is administered substantially simultaneously or sequentially with other agents useful in the treatment of said conditions, diseases or disorders, or said pain, migraine or inflammation.